FIRST REPORT OF THE PHASE-I STUDY OF THE NOVEL ORAL JAK2 INHIBITOR SB1518 IN PATIENTS WITH MYELOFIBROSIS

被引：0
|
作者：
Seymour, F. [1 ]
To, B. [2 ]
Goh, A. [3 ]
Meadows, L. [1 ]
Ethirajulu, A. [3 ]
Wood, A. [3 ]
Zhu, A. [4 ]
Roberts, W. [5 ]
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Australia
[2] Royal Adelaide Hosp, Inst Med & Vet Sci, Adelaide, SA 5000, Australia
[3] S BIO Pty Ltd, Singapore, Singapore
[4] S BIO Pty Ltd, Redwood City, CA USA
[5] Royal Melbourne Hosp, Parkville, Vic 3050, Australia
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1144
引用
收藏
页码：472 / 472
页数：1
相关论文
共 50 条
  • [41] Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
    Pemmaraju, Naveen
    Harrison, Claire
    Gupta, Vikas
    Verstovsek, Srdan
    Scott, Bart
    Oh, Stephen T.
    Palandri, Francesca
    Al-Ali, Haifa Kathrin
    Sobas, Marta
    McMullin, Mary Frances
    Mesa, Ruben
    Buckley, Sarah
    Roman-Torres, Karisse
    Vannucchi, Alessandro
    Yacoub, Abdulraheem
    EJHAEM, 2022, 3 (04): : 1346 - 1351
  • [42] Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis
    Verstovsek, Srdan
    Tefferi, Ayalew
    Korriblau, Steven
    Thomas, Deborah
    Cortes, Jorge
    Ravandi-Kashani, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2007, 110 (11) : 1037A - 1037A
  • [43] PHASE II STUDY OF CEP-701, AN ORALLY AVAILABLE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
    Santos, F. P. S.
    Kantarjian, H.
    Jain, N.
    Thomas, D.
    Garcia-Manero, G.
    Cortes, J.
    Verstovsek, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 439 - 439
  • [44] A phase 1 study of XL019 a selective JAK2 inhibitor, in patients with primary myelofibrosis and, post-polycythemia vera/essential thrombocythemia myelofibrosis
    Verstovsek, Srdan
    Pardanani, Animesh D.
    Shah, Neil P.
    Sokol, Lubomir
    Wadleigh, Martha
    Gilliland, D. Gary
    List, Alan F.
    Tefferi, Ayalew
    Kantarjian, Hagop M.
    Bui, Lynne A.
    Clary, Douglas O.
    BLOOD, 2007, 110 (11) : 170A - 170A
  • [45] A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis
    Pardanani, Animesh D.
    Gotlib, Jason
    Jamieson, Catriona
    Cortes, Jorge
    Talpaz, Moshe
    Stone, Richard M.
    Silverman, Michael H.
    Shorr, Jolene
    Gilliland, D. Gary
    Tefferi, Ayalew
    BLOOD, 2008, 112 (11) : 43 - 44
  • [46] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
    Jaekel, N.
    Behre, G.
    Behning, A.
    Wickenhauser, C.
    Lange, T.
    Niederwieser, D.
    Al-Ali, H. K.
    BONE MARROW TRANSPLANTATION, 2014, 49 (02) : 179 - 184
  • [47] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
    N Jaekel
    G Behre
    A Behning
    C Wickenhauser
    T Lange
    D Niederwieser
    H K Al-Ali
    Bone Marrow Transplantation, 2014, 49 : 179 - 184
  • [48] Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen K.
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Rivera, Candido E.
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2016, 128 (22)
  • [49] A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2015, 126 (23)
  • [50] A Phase 2 Study of Ruxolitinib, an Oral JAK1 and JAK2 Inhibitor, in Patients With Advanced Polycythemia Vera Who Are Refractory or Intolerant to Hydroxyurea
    Verstovsek, Srdan
    Passamonti, Francesco
    Rambaldi, Alessandro
    Barosi, Giovanni
    Rosen, Peter J.
    Rumi, Elisa
    Gattoni, Elisabetta
    Pieri, Lisa
    Guglielmelli, Paola
    Elena, Chiara
    He, Shui
    Contel, Nancy
    Mookerjee, Bijoyesh
    Sandor, Victor
    Cazzola, Mario
    Kantarjian, Hagop M.
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    CANCER, 2014, 120 (04) : 513 - 520
12345